NASDAQ$ZLAB
Zai Lab Limited-ADR · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Zai Lab's first quarter 2021 financial results were reported, showing solid revenue growth and strategic collaborations.
Zai Lab reported a net product revenue increase to $20.1 million, driven by ZEJULA and Optune, along with strategic collaborations to strengthen their oncology and autoimmune franchises. The company also significantly bolstered its capital position with a global public offering, but reported a net loss of $232.9 million due to increased R&D expenses from new business development activities.
- Entered strategic collaborations to strengthen gastric and lung cancer disease strongholds.
- Bolstered autoimmune franchise with an exclusive agreement for efgartigimod.
- Gained regulatory approval for QINLOCK, marking the third innovative oncology product approval in 15 months in China.
- Completed a global public offering with gross proceeds of nearly $860 million.
Headline financials
Revenue & EPS history
Zai Lab · Revenue · Quarterly
$20.1M
Revenue by segment
Zai Lab · $52M total across 3 segments · Q3 2023
- ZEJULA$41.6M+6.1%80.0%
- NUZYRA$5.5M+266.7%10.6%
- VYVGART franchise$4.9M—9.4%
Forward guidance
Zai Lab anticipates several milestones throughout 2021, including potential approval of Nuzyra, regulatory filings for margetuximab, Tumor Treating Fields, and ZEJULA in China, and numerous data readouts from ongoing clinical trials.
Tailwinds
- Expect approval of Nuzyra for CABP and ABSSSI by the NMPA.
- Plan to file margetuximab for Her2-positive breast cancer in China.
- Plan to file Tumor Treating Fields for mesothelioma in China.
- Plan to file ZEJULA for late-line ovarian cancer in China.
- Anticipate numerous data readouts for various assets in different cancer types.
Headwinds
- Potential delays in regulatory approvals.
- Uncertainties in clinical trial outcomes.
- Risks associated with commercializing new products.
- Dependence on partners for certain milestones.
- Impact of the COVID-19 pandemic on operations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
-0.1%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-0.5%
Avg return
30 days after
45%
13 / 29 earnings
Positive
+26.0%
Q1 2024
Best reaction
-11.2%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.9% | -7.0% | -20.9% | |
| Q4 2025 | +1.7% | -8.6% | -7.2% | |
| Q3 2025 | -6.4% | -11.3% | -21.4% | |
| Q1 2025 | +2.5% | +0.9% | +34.4% | |
| Q4 2024 | -2.0% | -3.1% | +6.3% | |
| Q3 2024 | -3.7% | -13.0% | -14.1% | |
| Q2 2024 | -5.6% | -7.8% | +11.3% | |
| Q1 2024 | +26.0% | +29.0% | +19.9% | |
| Q4 2023 | -0.9% | +0.5% | -23.7% | |
| Q3 2023 | +7.4% | +0.9% | -1.5% | |
| Q2 2023 | -11.2% | -5.4% | +3.5% | |
| Q1 2023 | +1.4% | -9.3% | -24.2% | |
| Q4 2022 | -0.6% | +7.3% | -10.5% | |
| Q3 2022 | +1.9% | +23.9% | +18.7% | |
| Q2 2022 | -5.0% | -6.2% | -8.0% | |
| Q1 2022 | -2.1% | +30.0% | +5.6% | |
| Q4 2021 | -4.0% | -26.0% | -19.6% | |
| Q3 2021 | +0.7% | -2.3% | -22.3% | |
| Q2 2021 | +0.6% | +0.9% | +0.4% | |
| Q1 2021 | -5.1% | -3.3% | +8.3% | |
| Q4 2020 | +0.3% | -7.0% | -9.6% | |
| Q4 2019 | -1.4% | -2.7% | +17.0% | |
| Q1 2020 | -8.7% | +3.1% | +18.3% | |
| Q2 2019 | +4.3% | +4.1% | -4.0% | |
| Q1 2019 | +3.7% | +6.7% | -9.7% | |
| Q4 2018 | +10.4% | +10.4% | +1.6% | |
| Q3 2018 | +6.7% | +13.6% | +13.1% | |
| Q4 2017 | -5.3% | -8.8% | +22.8% | |
| Q3 2017 | -2.2% | -0.6% | +0.3% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro